FILTER

Refine your search with the following facets to narrow down your results.

5 Current news of Octapharma

BAC and Octapharma extend collaboration for G-CSF custom ligand for commercial scale manufacture

18-Aug-2010 - BAC BV announced that it has entered into a licence agreement with Octapharma. Under the terms of the license, Octapharma can use BAC’s G-CSF CaptureSelect® custom affinity ligand for the purification of recombinant human granulocyte-colony stimulating factor (G-CSF) from human (HEK293F) cell ...

affinity chromatography antigens bone marrow +10

New High Purity Immunoglobulin Enters Phase III in Europe and the US

18-Feb-2010 - Octapharma AG announced the start of the first of a series of Phase III studies for its new 10% high purity intravenous immunoglobulin (IVIG). The study will investigate the efficacy and safety of this novel immunoglobulin in the treatment of primary immune deficiency and, together with results ...

Guillain-Barré syndrome idiopathic thrombocytopenic purpura immunotherapies +2

BAC and Octapharma Extend Recombinant Factor IX Collaboration for Clinical and Commercial Scale Production

04-Nov-2009 - BAC BV announced that it has entered into a licence agreement with Octapharma to use BAC’s anti-Factor IX CaptureSelect® affinity ligand in the large scale purification of recombinant Factor IX (FIX). Octapharma produces FIX for the treatment of bleeding in Haemophilia B. The licence agreement ...

antigens cell cultures hemophilia B +2

Fresenius Kabi and Octapharma Group enter into an Exclusive Agreement for a HESylated recombinant protein

30-Oct-2009 - Fresenius Kabi and Octapharma Group have signed a License, Development and Supply Agreement regarding the use of Fresenius Kabi’s HESylation® Technology to develop a HESylated recombinant protein. Under the agreement, Fresenius Kabi will license its proprietary HESylation® Technology to ...

Fresenius hydroxyethyl starch milestone payments +2

BAC and Octapharma to develop custom ligand for recombinant plasma protein

18-Mar-2008 - BAC BV announced that it has entered into a collaboration with Octapharma AG. The objective of the collaboration is to discover and develop a custom CaptureSelect(r) ligand for the purification of a recombinant Factor IX product, developed by Octapharma for the prophylaxis and treatment of ...

cell lines hemophilia B ligands +1